Scandinavian Chemotech Ab Stock Fundamentals
| CMOTEC-B | SEK 1.74 0.04 2.35% |
Scandinavian ChemoTech AB fundamentals help investors to digest information that contributes to Scandinavian ChemoTech's financial success or failures. It also enables traders to predict the movement of Scandinavian Stock. The fundamental analysis module provides a way to measure Scandinavian ChemoTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Scandinavian ChemoTech stock.
Scandinavian |
Scandinavian ChemoTech AB Company Current Valuation Analysis
Scandinavian ChemoTech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Scandinavian ChemoTech Current Valuation | 68.38 M |
Most of Scandinavian ChemoTech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scandinavian ChemoTech AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Scandinavian ChemoTech AB has a Current Valuation of 68.38 M. This is 99.52% lower than that of the Healthcare sector and 98.53% lower than that of the Biotechnology industry. The current valuation for all Sweden stocks is 99.59% higher than that of the company.
Scandinavian ChemoTech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Scandinavian ChemoTech's current stock value. Our valuation model uses many indicators to compare Scandinavian ChemoTech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Scandinavian ChemoTech competition to find correlations between indicators driving Scandinavian ChemoTech's intrinsic value. More Info.Scandinavian ChemoTech AB is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Scandinavian ChemoTech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Scandinavian ChemoTech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Scandinavian Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scandinavian ChemoTech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Scandinavian ChemoTech could also be used in its relative valuation, which is a method of valuing Scandinavian ChemoTech by comparing valuation metrics of similar companies.Scandinavian ChemoTech is currently under evaluation in current valuation category among its peers.
Scandinavian Fundamentals
| Return On Equity | -1.17 | |||
| Return On Asset | -0.51 | |||
| Operating Margin | (48.69) % | |||
| Current Valuation | 68.38 M | |||
| Shares Outstanding | 10.64 M | |||
| Shares Owned By Insiders | 26.03 % | |||
| Shares Owned By Institutions | 3.32 % | |||
| Price To Book | 8.87 X | |||
| Price To Sales | 159.69 X | |||
| Revenue | 49 K | |||
| Gross Profit | 2.86 M | |||
| EBITDA | (20.02 M) | |||
| Net Income | (17.74 M) | |||
| Cash And Equivalents | 5.62 M | |||
| Cash Per Share | 1.65 X | |||
| Total Debt | 53 K | |||
| Debt To Equity | 2.10 % | |||
| Current Ratio | 7.09 X | |||
| Book Value Per Share | 0.79 X | |||
| Cash Flow From Operations | (19.18 M) | |||
| Earnings Per Share | (2.19) X | |||
| Beta | 1.56 | |||
| Market Capitalization | 113.35 M | |||
| Total Asset | 25.81 M | |||
| Net Asset | 25.81 M |
About Scandinavian ChemoTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scandinavian ChemoTech AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scandinavian ChemoTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scandinavian ChemoTech AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Scandinavian ChemoTech AB provides cancer care and pain management solutions. Scandinavian ChemoTech AB is headquartered in Malmo, Sweden. Scandinavian ChemoTech is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Scandinavian Stock
Scandinavian ChemoTech financial ratios help investors to determine whether Scandinavian Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Scandinavian with respect to the benefits of owning Scandinavian ChemoTech security.